Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

NCT05981040 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: ZYIL1 capsules 25 mg and 50 mg Placebo
DRUG: ZYIL1 capsules 50 mg and 25 mg Placebo
DRUG: ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg
DRUG: Matching placebo 25 mg and Matching placebo 50 mg

Sponsor

Zydus Lifesciences Limited